KYMCO
16.11.2023 11:27:28 CET | Business Wire | Press release
Building on the pinnacle of over 25 years of EV innovation, KYMCO announced three ground-breaking technologies to accelerate the mass-adoption of electric motorcycles: The Ionex Battery-as-a-Service Solution for Energy Companies, the Ionex Battery Metering Unit for EV Manufacturers, and the Ionex Energy Station for Battery-swapping Network Operators. "Today, we stand on the brink of a remarkable transformation in the world of mobility. A shift that reshapes the way we move, a change that KYMCO leads," said Allen Ko, Chairman of KYMCO.
KYMCO's Vision: A World with Electric Motorcycles Everywhere
KYMCO sees Energy Companies provide riders with battery services for electric motorcycles. With this battery service, the riders receive batteries from energy companies with guaranteed performance and pay only for actual battery usage. Riders no longer need to buy batteries when purchasing their vehicle.
KYMCO sees EV Manufacturers introduce electric motorcycles with integrated onboard battery metering. Every electric motorcycle works with the Energy Companies' battery service. Without the costs of the batteries, electric motorcycles are more affordable than ever before.
KYMCO sees Battery-swapping Network Operators deploying thousands of battery-swapping stations, forever erasing range anxiety. Battery-swapping networks provide riders with zero-wait charging and unlimited range.
More profoundly, KYMCO sees riders choosing from a wide variety of electric motorcycles made by various manufacturers and battery service plans that best match their lifestyles. For energy replenishment, riders charge their vehicle in the garage or charge their battery in the house. In the city, riders swap on the go at the nearest battery-swapping station. And while traveling, riders get unlimited range from the extensive battery-swapping network to power all their journeys.
Ionex EV Solution: The True Arrival of the Electric Era
To address all current challenges and future ambitions to fulfill KYMCO's vision, Chairman Ko announced three ground-breaking technologies to propel all stakeholders to collaborate as the Ionex Open Consortium, an EV ecosystem that brings affordable, convenient, and sustainable electric mobility to all, the true arrival of the electric era.
The Ionex Battery-as-a-Service Solution for Energy Companies, the Ionex Battery Metering Unit for EV Manufacturers, and the Ionex Energy Station for Battery-swapping Network Operators make up the revolutionary Ionex EV Solution. The Ionex EV Solution aims to benefit every stakeholder in electric mobility, especially all consumers, businesses, and governments wishing to go electric.
"We look forward to seeing the impact the Ionex EV Solution will have on Southeast Asia's fast-developing EV ecosystem. We see its potential to bring about more affordable and convenient electric mobility," expressed Chuck Kim, Managing Director of Group Business Development and Capital Markets, Grab.
"Right here, right now, marks the inflection point of the electric era," said Allen Ko. "KYMCO's game-changing Ionex EV Solution is paving the way for all stakeholders to jointly transition to the electric future. I invite everyone to join us on this transformative journey."
About KYMCO
KYMCO is a brand with a rich history spanning nearly 60 years in the powersport industry. They focus on innovation, quality, style and have established themselves as a leading manufacturer of scooters, motorcycles, and ATVs worldwide. Their state-of-the-art manufacturing facilities and use of the latest technologies ensure that every vehicle they produce is reliable and stylish.
KYMCO is committed to reducing the environmental footprint, promoting sustainability, supporting social causes, and giving back to the communities. Whether riders seek a sleek and sporty scooter or a rugged and durable ATV, KYMCO has something for everyone. KYMCO is a brand that embodies the best of what the powersport industry offers - innovation, quality, style, and a commitment to making the world a better place.
You can learn more about KYMCO at www.kymco.com
Learn more about Ionex at www.ionexenergy.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231115883583/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
First Randomized Controlled Trial Shows Promise of a Ketogenic Diet in Psychotic Disorders8.7.2026 15:00:00 CEST | Press release
Trial reports correlations between ketone levels and cognitive and psychiatric symptoms in individuals with schizophrenia-spectrum and bipolar-1 disorders Published today in Schizophrenia Bulletin, a first-of-its-kind randomized controlled trial (RCT) from researchers at the University of California, San Francisco (UCSF), and funded in part by the National Institute of Mental Health (NIMH), adds to growing literature on the potential benefit of a ketogenic diet for treating psychotic disorders. The study, which enrolled participants with schizophrenia-spectrum or bipolar-1 disorders, demonstrated rapid metabolic improvements with a ketogenic diet compared to diet-as-usual during an initial one-month RCT open-label phase. Furthermore, those who continued with the optional four-month single-arm ketogenic diet extension saw meaningful gains across metabolic, psychiatric, and cognitive measures. This press release features multimedia. View the full release here: https://www.businesswire.co
Teamily AI Publicly Launches Human+AI Social Platform to Make Building and Growing a Company Easy for Every Team8.7.2026 15:00:00 CEST | Press release
Teamily AI (https://Teamily.ai), together with its Agentic AI Infra platform TensorOpera AI (https://TensorOpera.ai), today announced the public launch of its Human+AI social platform, a product stack that has already served more than 5 million users around the world. Starting today in Palo Alto and rolling out simultaneously across dozens of countries, this first public launch opens the full stack to everyone with a single mission: to make building and growing a company easy for every person and every team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708584390/en/ "This is the moment we open our doors to the world," said co-founders Dr. Aiden Chaoyang He and Professor Salman Avestimehr. "We want every person and every team to be able to move from idea to product, from product to market, and from market to growth and investment, with an AI-native team by their side." At its core, Teamily AI enables humans and AI agents
Leo Cancer Care Raises $65M Series D to Scale Its Integrated Upright Cancer Care Platform8.7.2026 14:30:00 CEST | Press release
Oversubscribed round follows the world-first compact upright proton treatment at Stanford Medicine — funding a single upright platform that will span imaging and treatment across multiple radiation modalities. Leo Cancer Care, the medical technology company working to reinvent how patients are imaged and treated by designing systems around the body’s natural upright position, today announced the close of an oversubscribed $65 million Series D financing. The round was led by Silicon Valley’s Yu Galaxy and welcomes new investors including Eventide Asset Management, alongside continued support from the company’s existing investors. Leading cancer institutions are already adopting the upright approach. Stanford Medicine delivered the world’s first compact upright proton therapy treatment on 4 June 2026. Dana-Farber Cancer Institute and McLaren Health Care are among the institutions bringing the upright platform into their programmes — adoption that spans world-leading academic centers and
LUMI AI Factory Selects IQM to Deploy Advanced Quantum Computer, Accelerating Hybrid HPC and AI Development8.7.2026 14:00:00 CEST | Press release
The Halocene H4 quantum computer, named LUMI-IQ, will be delivered and installed in 2027 The system will be hosted at CSC – IT Center for Science in Finland and integrated into the LUMI AI Factory The system will provide researchers, industry innovators, and developers across Europe with a unique, advanced experimental platform where quantum computing and artificial intelligence converge The LUMI AI Factory, led by CSC – IT Center for Science, has selected IQM Quantum Computers (Nasdaq: IQMX) to deliver IQM Halocene H4, an advanced quantum computer aimed at accelerating hybrid high-performance computing, artificial intelligence, and quantum computing capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708006791/en/ LUMI AI Factory selects IQM to deploy advanced quantum computer, accelerating hybrid HPC and AI development IQM Halocene H4 is the first and most advanced on-premises superconducting quantum computer o
Merck Announces FDA Breakthrough Therapy Designation for Enpatoran in Lupus Patients With Active Skin Manifestations8.7.2026 14:00:00 CEST | Press release
Enpatoran could address a significant unmet need in lupus, specifically targeting cutaneous manifestations of the disease, which currently have no approved therapiesFDA's decision was supported by Phase 2 WILLOW study results, which demonstrated meaningful symptoms improvement, particularly among patients with active cutaneous manifestationsEnpatoran's potential to go beyond current treatment standards in lupus prompted FDA´s breakthrough designation, which is designed to expedite drug development and reviewNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to enpatoran for the treatment of lupus with active cutaneous manifestations. Enpatoran is an oral selective toll-like receptor (TLR) 7/8 inhibitor, designed to modulate pathways central to lupus-related inflammation. “For the 85% of lupus patients whose disease includes skin manif
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom